Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of the Cryopreserved Amniotic Membranes in the Care of Resistant Vascular Ulcers (MAUV)

This study has been terminated.
(clinical trial have encountered difficulties enrolling a sufficient number of patients)
Etablissement Français du Sang
Information provided by (Responsible Party):
University Hospital, Limoges Identifier:
First received: January 9, 2009
Last updated: March 22, 2014
Last verified: December 2013

To evaluate tolerance and efficiency of cryopreserved amniotic membranes in local treatment of resistant vascular ulcers.

To evaluate complete cicatrisation, efficiency on pain, prevention of infection, improvement of quality of life.

To evaluate rate of amputations and recurrence at one year after complete cicatrisation

Condition Intervention Phase
Resistant Vascular Ulcers
Procedure: amniotic membranes
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Evaluation of the Cryopreserved Amniotic Membranes in the Care of Resistant Vascular Ulcers

Further study details as provided by University Hospital, Limoges:

Primary Outcome Measures:
  • Measure of the diameter of the ulcer [ Time Frame: Every week ] [ Designated as safety issue: No ]

Enrollment: 10
Study Start Date: January 2009
Estimated Study Completion Date: June 2014
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: amniotic membranes Procedure: amniotic membranes
The amniotic membrane is taken with a sterile crowbar then applied side foetal face against the ulcer and displayed in a homogeneous way

Detailed Description:

Treatment of patients suffering from vascular ulcers or amputation's wound from at least 6 months after or without possibility for surgical treatment. A cryopreserved amniotic membrane, obtained after caesarean from consenting women without any disease, is applied on the ulcer after serological checking and changed once a week.

Main criterias:

Tolerance will be evaluated on clinical criterias. Efficiency will be evaluated by measuring reduction of ulcer's area (reduction of at least 50 % at 6 months).

Secondary criterias:

Reduction of pain will be evaluated by analogic visual scale and evaluation of analgesic consumption.

Evaluation of infections, amputations, complete healing, improvement of quality of life by SF36 questionnaire and recurrence at one year for patients with complete healing.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Obtained informed consent
  • Leg or foot arterial or mixed ulcer older than at least 3 months

Exclusion Criteria:

  • No obtained informed consent
  • Possibility for surgical treatment (revascularisation)
  • Age less than 18
  • Pregnancy
  • Indication for major amputation (below /above the knee)
  • Venous ulcer
  • Ulcer with infection and / or necrosis
  • Mycotic ulcer
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00820274

Service de Chirurgie Vasculaire et Viscérale
Bordeaux, France, 33076
Service de Médecine Interne et Pathologie Vasculaire
Bordeaux, France, 33075
Service de Chirurgie Thoracique, cardiovasculaire et angiologie
Limoges, France, 87000
Sponsors and Collaborators
University Hospital, Limoges
Etablissement Français du Sang
Principal Investigator: Francis Pesteil, MD CHU Limoges
  More Information

No publications provided

Responsible Party: University Hospital, Limoges Identifier: NCT00820274     History of Changes
Other Study ID Numbers: I07011
Study First Received: January 9, 2009
Last Updated: March 22, 2014
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:
Pathologic Processes processed this record on November 23, 2014